Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

作     者：Koji Miyahara Kazuhiro Nouso Kazuhide Yamamoto 

作者机构：Department of Gastroenterology and HepatologyOkayama University Graduate School of MedicineDentistryand Pharmaceutical SciencesOkayama-cityOkayama 700-8558Japan Department of Molecular HepatologyOkayama University Graduate School of MedicineDentistryand Pharmaceutical SciencesOkayama-cityOkayama 700-8558Japan 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第15期

页      面：4151-4159页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Biomarker Molecular targeted therapy Clinical trial Hepatic arterial infusion chemotherapy Hepatocellular carcinoma Sorafenib 

摘      要：The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma(HCC).After development of sorafenib and its introduction as a therapeutic agent used in the clinic,several critical questions have been *** parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be *** it is difficult to know the responders in advance using conventional characteristics of patients,there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of *** and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet *** addition,effectiveness of the expanded application of sorafenib is still controversial,although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage ***,over 50 relevant drugs have been developed and are currently under *** efficacy of some of these drugs has been extensively examined,but none have demonstrated any superiority over sorafenib,so ***,there are several drugs that have shown efficacy for treatment after sorafenib failure,and these are proceeding to further *** address these issues and questions,we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib.